# Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

> **NCT00206661** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 22 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Sargramostim (Leukine)
- **DRUG:** Sargramostim (Leukine)

## Key facts

- **NCT ID:** NCT00206661
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206661, "Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00206661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*